Key result
Oral lacidipine lowers peripheral resistance with reflex tachycardia, showing under 10% bioavailability.
Why the study?
The safety, tolerability, pharmacodynamic, and pharmacokinetic profiles of lacidipine were assessed in various populations including normotensive and special patient groups.
What are the safety, tolerability, and pharmacokinetic/pharmacodynamic profiles of lacidipine in human subjects?
What are the safety, tolerability, and pharmacokinetic/pharmacodynamic profiles of lacidipine in human subjects?
Lacidipine is a calcium channel blocker with low absolute bioavailability that reduces peripheral vascular resistance without affecting cardiac pacemaker tissue.
No takes yet. Share an insight, caveat, or question.
Lacidipine's vasodilatory effects with reflex compensation in normotensives should not change practice; leaves open its antihypertensive utility pending randomized trials.
Hall et al. (1991) conducted a review in Healthy volunteers and specific patient populations. Lacidipine vs. Nifedipine 10 mg was evaluated on Pharmacodynamic and pharmacokinetic profiles, safety, and tolerability. Single oral doses of 3-5 mg of lacidipine produced a dose-related fall in peripheral vascular resistance with reflex increases in heart rate, and absolute bioavailability was less than 10%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: